Urticaria Facticia Treatment With Omalizumab (UFO)

Inclusion Criteria: * Adults (18-75 years) * Informed consent signed and dated * Able to read, understand and willing to sign the informed consent form and abide with study procedures * Diagnosis of UF lasting for at least 6 months * Willing, committed and able to return for all clinic visits and complete all study-related procedures, including willingness to have SC injections administered by a qualified person * In females of childbearing potential: Negative pregnancy test; females willing to use highly effective contraception (Pearl-Index \< 1). A woman will be considered not of childbearing potential if she is post-menopausal for greater than two years or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) * No participation in other clinical trials 4 weeks before and after participation in this study Exclusion Criteria: * Patients with acute urticaria * Concurrent/ongoing treatment with immunosuppressives (e.g. systemic steroids, cyclosporine, methotrexate, dapsone or others) within 4 weeks or 5 half lives prior to day 0, whichever is longer * Significant medical condition rendering the patient immunocompromised or not suitable for a clinical trial * Significant concomitant illness that would adversely affect the subject's participation or evaluation in this study * History of malignancies within five years prior to screening other than a successfully treated non-metastatic cutaneous, basal, or squamous cell carcinoma and/or in situ cancer * Presence of clinically significant laboratory abnormalities * Lactating females or pregnant females * Subjects for whom there is concern about compliance with the protocol procedures * Any medical condition which, in the opinion of the Investigator, would interfere with participation in the study or place the subject at risk * History of substance abuse (drug or alcohol) or any other factor (e.g., serious psychiatric condition) within the last 5 years that could limit the subject's ability to comply with study procedures * Subjects who are detained officially or legally to an official institute * Previous use of omalizumab within the last 6 months * Intake of antihistamines or leukotriene antagonists within 4 days prior to visit 1 * Intake of oral corticosteroids within 14 days prior to visit 1 * Use of depot corticosteroids or chronic systemic corticosteroids within 21 days before beginning of the study * Known hypersensitivity to any ingredients, including excipients (sucrose, histidine, polysorbate 20) of the study medication or drugs related to omalizumab (e.g.: monoclonal antibodies, polyclonal gammaglobulin)